Schering aquires CIS bio international
CIS specialises in the development, production, marketing and distribution of radiopharmaceuticals for diagnosis and therapy. CIS also has a strong portofolio and reputation in the in-vitro diagnostic field, radioimmunology and Drug screening.
"The acquisition and integration of CIS into Schering AG's worldwide activities supports Schering AG's strategy to become a substantial player in the global radiopharmaceutical market," said Hans-Michael Rook, Head of Diagnostics and Radiopharmaceuticals at Schering AG. "The area of oncological radiopharmaceuticals presents a particularly attractive opportunity given Schering AG's existing expertise in oncology and the potential for synergies between its diagnostics and therapeutics businesses".
Most read news
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.